Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy

Nature(2021)10.1038/s41586-021-04017-wSource: DataRank Database

Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy is a research paper published in Nature (2021). On theSindex it has a DataRank of 6.0. It has been cited 200 times, with 180 citing works in its 1-hop citation network.

N/A

6.0DataRank · unranked

Scored on demand from live citation data

Open Access200 citations · 180 citing works in its network

Download PDF

Cite:

Linked data & code

nct pdb

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (10 grants)Impact (FWCI 10.25)OA: bronzeTopics (68)Linked Datasets (2)DataCite Reuse (2)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 13%Citation Network 87%

Base Score Contribution

0.795

From this paper's citation signal

Citation Network Contribution

5.2

From 151 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 180 citers.

An aberrant inflammatory response in severe COVID-19
Cell Host & Microbe202139 citations20 referencesContributes 0.184
Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody
Cell2022189 citations38 referencesContributes 0.138
Anti-SARS-CoV-2 antibodies elicited by COVID-19 mRNA vaccine exhibit a unique glycosylation pattern
Cell Reports202169 citations39 referencesContributes 0.109
Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains
Nature Communications2022154 citations49 referencesContributes 0.103
Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants
Virologica Sinica202227 citations34 referencesContributes 0.098

Authors (11)

Andrew Jones ORCID,Hans-Heinrich Hoffmann ORCID,Alexandra Schäfer ORCID,Kevin S. Kao ORCID,Rebecca Francis ORCID

Live enrichment

PubMed:34547765 PMC:PMC9038156 OpenAlex:https://openalex.org/W3199974613

NIAID NIH HHS

Grant: R01 AI145870

NIAID NIH HHS

Grant: R01 AI137276

NCI NIH HHS

Grant: P30 CA008748

NIAID NIH HHS

Grant: R01 AI157155

NIAID NIH HHS

Grant: U19 AI111825

National Institutes of Health

Grant: 3R01AI145870-02S1

Evaluation of the FcgR mechanisms in the antibody-dependent enhancement of SARS-CoV-2 infection

National Institutes of Health

Grant: 2P30CA008748-43

MOUSE GENETICS

National Institutes of Health

Grant: 5U19AI111825-02

Modulation of Human Dendritic Cell Development by Adjuvants and Vaccines

National Institutes of Health

Grant: 5R01AI157155-02

Human antibody-based countermeasures against the Coronavirus SARS-CoV-2

National Institutes of Health

Grant: 5R01AI137276-08

Mechanisms of Antibody-Dependent Enhancement of Dengue Disease

FWCI

10.25

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

bronzeLicense: Springer TDM

journalhttps://www.nature.com/articles/s41586-021-04017-w.pdf

publisherhttps://www.nature.com/articles/s41586-021-04017-w.pdf

publisherhttps://www.nature.com/articles/s41586-021-04017-w

journalhttps://doi.org/10.1038/s41586-021-04017-w

repositoryhttps://pubmed.ncbi.nlm.nih.gov/34547765

Fields of Study

SARS-CoV-2 and COVID-19 ResearchMonoclonal and Polyclonal Antibodies ResearchCOVID-19 Clinical Research Studies0301 basic medicine03 medical and health sciencesAnimalsAntibodies, MonoclonalAntibodies, NeutralizingCOVID-19CricetinaeDisease Models, AnimalFemaleHumansImmunoglobulin Fc FragmentsImmunoglobulin GMaleMicePre-Exposure ProphylaxisReceptors, IgGSARS-CoV-2Treatment OutcomeCOVID-19 Drug Treatment

MeSH Terms

COVID-19SARS-CoV-2COVID-19 Drug TreatmentAnimalsAntibodies, MonoclonalDisease Models, AnimalFemaleCricetinaeHumansImmunoglobulin GImmunoglobulin Fc FragmentsMaleTreatment OutcomeReceptors, IgGMiceAntibodies, NeutralizingPre-Exposure Prophylaxis

Keywords

Monoclonal antibodyAntibodyMedicineImmunologyCoronavirus disease 2019 (COVID-19)DiseaseSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)EffectorVirologyMonoclonalInfectious disease (medical specialty)Internal medicineMaleSARS-CoV-2Receptors, IgGAntibodies, MonoclonalCOVID-19Antibodies, NeutralizingImmunoglobulin Fc FragmentsCOVID-19 Drug TreatmentDisease Models, AnimalMiceTreatment OutcomeCricetinaeImmunoglobulin GAnimalsHumansFemalePre-Exposure Prophylaxis

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Additional file 1 of Structural properties of immune complexes formed by viral antigens and specific antibodies shape the inflammatory response of macrophages

10.6084/m9.figshare.26712449.v1figshare

Additional file 1 of Structural properties of immune complexes formed by viral antigens and specific antibodies shape the inflammatory response of macrophages

10.6084/m9.figshare.26712449figshare